Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ian Roger Moore
Date of last notice	4 January 2017

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect.	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Moore and Sotomi Investments Pty Ltd <roger a="" c="" family="" moore=""> Mr Moore is a director and shareholder of the</roger>	
	trustee and a beneficiary of the trust.	
Date of change	8 and 12 September 2017	
No. of securities held prior to change	187,000 fully paid ordinary shares ("Shares")	
Class	Shares	
Number acquired	65,000 Shares	
Number disposed	Nil.	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$13,041 (\$0.20 per Share)	
No. of securities held after change	252,000 Shares.	

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Manage of manifestanced healther	
Name of registered holder	
(if issued securities)	
,	
Date of change	
•	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in relation to which the interest has changed	
to which the interest has changed	
Interest acquired	
•	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash, provide details and	
an estimated valuation	
Interest after change	
_	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.